NYSE:TMBR Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free TMBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.34▼$2.9452-Week Range N/AVolume26,307 shsAverage Volume511,937 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Timber Pharmaceuticals alerts: Email Address Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About Timber Pharmaceuticals Stock (NYSE:TMBR)Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.Read More Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. TMBR Stock News HeadlinesMay 13, 2024 | reuters.comCan timber construction overcome its growing pains?March 10, 2024 | businesswire.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingJanuary 28, 2024 | msn.comTimber Pharmaceuticals Announces Official Name ChangeJanuary 13, 2024 | uk.investing.comTimber Pharmaceuticals Inc (TMBRQ)November 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)November 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 21, 2023 | seekingalpha.comMVST, FBIO and VTVT among mid-day moversNovember 17, 2023 | msn.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 16, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerSeptember 18, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceAugust 29, 2023 | 247wallst.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 28, 2023 | msn.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 21, 2023 | benzinga.comTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | markets.businessinsider.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | msn.comTimber to be taken private by LEO Pharma, stock soars 100%August 21, 2023 | investorplace.comWhy Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?August 21, 2023 | markets.businessinsider.comUS Stocks Mostly Higher; Nasdaq Jumps 100 PointsAugust 21, 2023 | marketwatch.comTimber Pharmaceuticals Shares Soar on Takeover by LEO PharmaAugust 21, 2023 | benzinga.comWhy Timber Pharmaceuticals Stock Is Skyrocketing TodayAugust 21, 2023 | finance.yahoo.comLEO Pharma Signs Agreement to Acquire Timber PharmaceuticalsAugust 21, 2023 | finance.yahoo.comTimber Pharmaceuticals to be Acquired by LEO PharmaAugust 15, 2023 | morningstar.comTimber Pharmaceuticals Inc Ordinary SharesJuly 3, 2023 | finance.yahoo.comTimber Pharmaceuticals Discloses Communication From NYSE AmericanSee More Headlines Receive TMBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:TMBR CUSIPN/A CIK1504167 Webwww.timberpharma.com Phone(973) 314-9577FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-511.45% Return on Assets-180.93% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / BookN/AMiscellaneous Outstanding Shares3,430,000Free Float3,378,000Market Cap$1.21 million OptionableNot Optionable Beta0.03 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. John Koconis M.B.A. (Age 53)Chairman, CEO & President Comp: $570.19kMr. Joseph Lucchese (Age 56)Executive VP, CFO, Treasurer & Secretary Comp: $542.3kDr. Alan Mendelsohn M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $507.16kKey CompetitorsProcessa PharmaceuticalsNASDAQ:PCSABright Minds BiosciencesNASDAQ:DRUGHoth TherapeuticsNASDAQ:HOTHVirios TherapeuticsNASDAQ:VIRIChina PharmaNYSE:CPHIView All Competitors TMBR Stock Analysis - Frequently Asked Questions Should I buy or sell Timber Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares. View TMBR analyst ratings or view top-rated stocks. When did Timber Pharmaceuticals' stock split? Timber Pharmaceuticals's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. This page (NYSE:TMBR) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Timber Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Timber Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.